ArticleClinical journal of gastroenterology2026
Contrast-enhanced endoscopic ultrasonography differentiated pancreatic schwannoma from concurrent neuroendocrine tumor.
Article in Clinical journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic schwannomas are extremely rare and their variable imaging features on computed tomography (CT) and magnetic resonance imaging (MRI) make preoperative diagnosis challenging. A 73 year-old man was incidentally found to have a 13 mm hypoechoic mass in the pancreatic body on transabdominal ultrasonography. CT showed delayed enhancement, and MRI demonstrated hypointensity on T1, slight hyperintensity on T2, and hyperintensity on diffusion-weighted imaging (DWI). On endoscopic ultrasonography (EUS), the lesion appeared as a 13 mm hypoechoic mass, and contrast-enhanced EUS revealed gradual isoenhancement beginning 17 s after contrast injection. Another 6 mm hypoechoic lesion was identified in the pancreatic tail on EUS, and contrast-enhanced EUS showed rapid hyperenhancement beginning 12 s after contrast injection. EUS-guided fine-needle aspiration (EUS-FNA) was performed for both lesions, which were diagnosed as schwannoma and Grade 1 neuroendocrine tumor, respectively. A strategy of observation was adopted for both tumors. This is a rare case of concomitant pancreatic schwannoma and NET. EUS contributed to the detection of a small NET, while contrast-enhanced EUS revealed different vascular patterns between the two lesions, leading to a decision to perform EUS-FNA for both tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.